Romosozumab group: Patients receive romosozumab subcutaneously. After 52 weeks of treatment, romosozumab will be discontinued and denosumab will be started. At week 156, final observation is performed
Sponsors
Division of Rheumatology, Department of Internal Medicine, Toho University School of Medicine
Conditions
glucocorticoid-induced osteoporosis
Unknown Phase
A comparative study of the efficacy and safety of romosozumab and teriparatide for glucocorticoid-induced osteoporosis 1
RecruitingJPRN-UMIN000056386
Start: 2025-08-26Target: 100Updated: 2026-06-29
A comparative study of the efficacy and safety of romosozumab and teriparatide for glucocorticoid-induced osteoporosis 2
Active, not recruitingJPRN-UMIN000056395
Start: 2025-02-01Target: 100Updated: 2026-06-29